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Objectives
There is strong current interest in the use of biodegrad-
able scaffolds in combination with bone growth factors
as a valuable alternative to the current gold standard
autograft in spinal fusion surgery (Yong et al. 2013).
Here we report on 6- vs 12- month data set evaluating
the longitudinal performance of a CaP coated polycapro-
lactone (PCL) scaffold loaded with recombinant human
bone morphogenetic protein-2 (rhBMP-2) as a bone
graft substitute within a preclinical ovine thoracic spine.
Material and methods
Twelve sheep underwent a 3-level (T6/7, T8/9 and T10/11)
discectomy with randomly allocated implantation of a dif-
ferent graft substitute at each of the three levels; (i) calcium
phosphate (CaP) coated polycaprolactone based scaffold
plus 0.54mcg rhBMP-2, (ii) CaP coated PCL- based scaffold
alone or (iii) autograft (mulched rib head). Fusion assess-
ments were performed via high resolution clinical com-
puted tomography and histological evaluation were
undertaken at six (n=6) and twelve (n=6) months
post-surgery using the Sucato grading system (Sucato
et al. 2004).
Results
The computed tomography fusion grades of the 6- and
12- months in the rhBMP-2 plus PCL- based scaffold
group were 1.9 and 2.1 respectively, in the autograft
group 1.9 and 1.3 respectively, and in the scaffold alone
group 0.9 and 1.17 respectively. There were no statisti-
cally significant differences in the fusion scores between
6- and 12- month for the rhBMP plus PCL- based scaf-
fold or PCL - based scaffold alone group however there
was a significant reduction in scores in the autograft
group. These scores were seen to correlate with histolo-
gical evaluations of the respective groups.
Conclusions
The results of this study demonstrate the efficacy of
scaffold-based delivery of rhBMP-2 in promoting higher
fusion grades at 6- and 12- months in comparison to
the scaffold alone or autograft group within the same
time frame. Fusion grades achieved at six months using
PCL+rhBMP-2 are not significantly increased at twelve
months post surgery.
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